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ABSTRACT
Objective Interleukin (IL)-17A producing CD4 T-cells
(TH-17 cells) are implicated in rheumatoid arthritis (RA).
IL-6/STAT3 signalling drives TH-17 cell differentiation,
and hyperactive gp130/STAT3 signalling in the gp130F/F
mouse promotes exacerbated pathology. Conversely,
STAT1-activating cytokines (eg, IL-27, IFN-γ) inhibit
TH-17 commitment. Here, we evaluate the impact of
STAT1 ablation on TH-17 cells during experimental
arthritis and relate this to IL-17A-associated pathology.
Methods Antigen-induced arthritis (AIA) was
established in wild type (WT), gp130F/F mice displaying
hyperactive gp130-mediated STAT signalling and the
compound mutants gp130F/F:Stat1−/− and gp130F/F:
Il17a−/− mice. Joint pathology and associated peripheral
TH-17 responses were compared.
Results Augmented gp130/STAT3 signalling enhanced
TH-17 commitment in vitro and exacerbated joint
pathology. Ablation of STAT1 in gp130F/F mice (gp130F/F:
Stat1−/−) promoted the hyperexpansion of TH-17 cells in
vitro and in vivo during AIA. Despite this heightened
peripheral TH-17 cell response, disease severity and the
number of joint-inﬁltrating T-cells were comparable with
that of WT mice. Thus, gp130-mediated STAT1 activity
within the inﬂamed synovium controls T-cell trafﬁcking
and retention. To determine the contribution of IL-17A,
we generated gp130F/F:IL-17a−/− mice. Here, loss of
IL-17A had no impact on arthritis severity.
Conclusions Exacerbated gp130/STAT-driven disease in
AIA is associated with an increase in joint inﬁltrating
T-cells but synovial pathology is IL-17A independent.
INTRODUCTION
Interleukin (IL)-17A is increasingly linked with
chronic disease progression, and several targeted
therapies against IL-17A are in clinical develop-
ment.1–5 IL-17A-producing CD4 T-cells (TH-17 cells)
are widely acknowledged as pathogenic in many
diseases, including rheumatoid arthritis (RA).1 6
Here, IL-17A production by T-cells contributes to
synovial inﬂammation through regulation of proin-
ﬂammatory cytokines and chemokines (IL-1β,
tumour necrosis factor (TNF)-α, IL-6, granulocyte/
macrophage-colony stimulating factor (GM-CSF),
receptor activator of nuclear factor-kappa-B ligand
(RANKL), CC-chemokine ligand 20 (CCL20)), and
the control of matrix metalloproteinases and
osteoclastogenic processes.6–9 Consequently, in
experimental arthritis, IL-17A deﬁciency or blockade
of IL-17A signalling reduces inﬂammation-
associated joint pathology.10
While cytokines including transforming growth
factor-β (TGF-β), IL-6, IL-21 and IL-231 promote
TH-17 effector functions murine TH-17 differenti-
ation is dependent on TGF-β and IL-6.11 IL-6 sti-
mulates cells through a non-signalling IL-6R
α-chain and gp130, which activates signal trans-
ducer and activator of transcription 1 (STAT1) and
STAT3, and represents the signalling β-receptor for
IL-6-related cytokines.12 Mice displaying enhanced
gp130-mediated STAT1 and STAT3 signalling, as a
consequence of a phenylalanine (F) knock-in substi-
tution of the cytoplasmic tyrosine (Y)757 residue in
gp130 (gp130F/F mice) show exacerbated joint
pathology in experimental arthritis.13 Here, disease
was linked to gp130-driven STAT3 and was asso-
ciated with increased synovial T-cell production of
IL-17A.13 However, the role of gp130-mediated
STAT1 signalling during inﬂammatory arthritis is ill
deﬁned. STAT1 activity often counteracts STAT3
transactivation, and recent data highlight an inhibi-
tory role in TH-17 differentiation.
14 Here, we
investigate STAT1 control of TH-17 responses
during experimental arthritis and determine the
role of gp130-regulated IL-17A in arthritis
pathology.
METHODS
Mice
The generation of gp130F/F and gp130F/F com-
pound mutant mice homozygous null for Stat1
(gp130F/F:Stat1−/−) or Il17a (gp130F/F:Il17a−/−)
and heterozygous for the Stat3 (gp130F/F:Stat3+/−)
genes have been described previously.15 16 Mice
were bred and maintained under speciﬁed
pathogen-free conditions.
T-cell cultures
Splenic T-cells were cultured in RPMI-1640 supple-
mented with 10% (v/v) foetal calf serum (FCS),
2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL
streptomycin, 1 mM sodium pyruvate and 50 mM
2-mercaptoethanol (all from Life Technologies).
A total of 1×105 cells/well were cultured in 96-well
plates, and T-cells activated by plate-bound anti-CD3
(1 mg/mL; 45-2C11; R&D Systems) and soluble
anti-CD28 (5 mg/mL; 37.51; BD Biosciences).
Cultures were supplemented with TGF-β (1 ng/mL;
R&D Systems) and IL-6 (10 ng/mL; R&D Systems)
and incubated at 37°C for 4 days before evaluation
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of TH-1 and TH-17 polarisation by ﬂow cytometry (see online sup-
plementary methods).
Antigen-induced arthritis
Experiments were performed on 8–12-week-old mice in accord-
ance with UK Home Ofﬁce Project License PPL-30/2361.
Antigen-induced arthritis (AIA) was induced as previously
described and disease severity determined by histological assess-
ment of knee-joint sections.13 See online supplementary
methods for further details.
Statistics
Disease activity was statistically evaluated using the non-
parametric Mann–Whitney U test. Otherwise, differences were
determined using an unpaired Student t test. In all cases,
p<0.05 was considered signiﬁcant.
RESULTS
T-cells from gp130F/F mice lacking STAT1 exhibit
hyperexpansion of TH-17 cells
We have previously shown that gp130F/F mice display exacer-
bated histopathology in experimental arthritis, as a consequence
of elevated STAT3 signalling.13 In this respect, the severity of
joint pathology was associated with increased inﬁltration of syn-
ovial IL-17A-producing T-cells.13 Enhanced gp130-mediated
STAT3 activity promotes TH-17 differentiation in vitro.
16
However, STAT1 activating cytokines (eg, IFN-γ and IL-27)
inhibit TH-17 differentiation, and are protective in experimental
arthritis.14 17 18 Thus, a balance between gp130-mediated
STAT1 and STAT3 signalling would be predicted to inﬂuence
the course of disease. To test this, we ﬁrst considered the impact
of STAT1 deletion on TH-17 development in T-cell cultures
from gp130F/F:Stat1−/− compound mice (ﬁgure 1). Compared
with wild type (WT) controls, T-cells from gp130F/F mice
showed more than a twofold increase in the proportion of CD4
IL-17A+ T-cells when cultured under TH-17 polarising condi-
tions (ﬁgure 1A,B). This response was STAT3 dependent as the
proportion of CD4 IL-17A+ T-cells from gp130F/F:Stat3+/−
mice were signiﬁcantly reduced and TH-17 expansion was com-
parable with that seen in WT mice (ﬁgure 1A,B). Conversely, a
loss of STAT1 signalling in gp130F/F:Stat1−/− T-cell cultures
caused a ‘hyperexpansion’ of TH-17 cells (ﬁgure 1A,B), which
was further reﬂected by the quantiﬁcation of IL-17A in culture
supernatants (ﬁgure 1C). While no differences were observed in
the frequency of IFN-γ-producing TH-1 cells between the
genetic strains, the proportion of IFN-γ+IL-17A+ double produ-
cers was elevated in gp130F/F:Stat1−/− T-cell cultures (see online
supplementary ﬁgure S1). Thus, altered bioavailability of
gp130-mediated STAT1 and STAT3 signalling dramatically
skews TH-17 commitment in vitro.
Increased TH-17 responses in gp130
F/F:Stat1−/− mice do not
enhance arthritis severity
To determine the in vivo consequence of STAT1 deletion in
experimental arthritis, AIA was established in gp130F/F:Stat1−/−
mice (ﬁgure 2). On day 10 of arthritis induction, inguinal lymph
Figure 1 T-cells from gp130F/F:Stat1−/− mice are hyper-responsive to TH-17 polarisation. (A) Representative ﬂow cytometric analysis of the
development of IL-17A producing CD4 T-cells from (WT), gp130F/F (FF), gp130F/F:Stat3+/− (FFSt3) and gp130F/F:Stat1−/− (FFSt1) mice cultured under
TH-17 polarising conditions (TGF-β and IL-6). (B) Percentage of CD4 IL-17A
+-producing cells generated under TH-17 polarising conditions for each
mouse genotype (C) ELISA measurements of IL-17A protein concentrations in splenic T-cell culture supernatants. Data are presented as mean±SD of
three independent experiments (**p<0.01, ***p<0.001). WT, wild type.
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nodes were isolated and the number of TH-17 cells compared
with those observed in gp130F/F and WT mice (ﬁgure 2A). Here,
gp130F/F:Stat1−/− mice displayed a heightened peripheral TH-17
response, reﬂecting our in vitro observations and supporting a
role for STAT1 as a negative regulator of TH-17 expansion in
vivo. The increased peripheral response was not, however,
limited to TH-17 cells as gp130
F/F:Stat1−/− mice also displayed
elevated total CD4 and TH-1 cell numbers (ﬁgure 2A). While
gp130F/F:Stat1−/− mice displayed an increased expansion in abso-
lute TH-1 and TH-17 cell numbers compared with WT and
gp130F/F mice, the proportion of CD4 T-cells secreting IFN-γ
and IL-17A was comparable between genotypes (ﬁgure 2A and
see online supplementary table S1). This increase in peripheral
T-cell commitment did not, however, equate to worse joint path-
ology during the T-cell prominent phase of the model (day-10).
While gp130F/F mice displayed exacerbated disease, gp130F/F:
Stat1−/− mice showed attenuated histopathology and scores were
comparable with WT mice (ﬁgure 2B). Also, immunohistochem-
istry (IHC) for synovial CD3 T-cells demonstrated a dramatic
reduction of inﬁltrates in gp130F/F:Stat1−/− mice compared with
gp130F/F joints (IHC CD3 score of 1.2±0.4 compared with 3.5
±0.4 respectively; ﬁgure 2C). Synovial STAT1 signalling there-
fore contributes to gp130-driven joint inﬂammation. These ﬁnd-
ings illustrate two contrasting STAT1 activities for the control of
T-cell responses, where STAT1 negatively regulates peripheral
T-cell expansion, but supports local effector cell recruitment.
IL-17A does not drive arthritis pathology in gp130F/F mice
We previously observed an association between joint inﬁltrating
IL-17A producing T-cells and exacerbated AIA in gp130F/F
mice.13 While gp130F/F:Stat1−/− mice displayed exaggerated
peripheral T-cell responses, the failure to recruit these cells to
the inﬂamed joint during AIA prevented us from determining
the contribution of TH-17 cells to local joint pathology. We
therefore generated gp130F/F:Il17a−/− compound mice to inves-
tigate the importance of the TH-17 signature cytokine, IL-17A,
in local joint pathology. Consistent with our previous data,13
end-stage histopathology (day-28 & 35) was exacerbated in AIA
challenged gp130F/F mice (see online supplementary table S2).
However, comparison of gp130F/F and gp130F/F:Il17a−/− mice
Figure 2 Heightened peripheral TH-17 cell responses in gp130
F/F:Stat1−/− mice during antigen-induced arthritis (AIA) is not associated with
exacerbated joint pathology. (A) AIA was established in wild type (WT), gp130F/F (FF) and gp130F/F:Stat1−/− (FFSt1) mice and the number of
peripheral CD4, TH-17 and TH-1 cells assessed by ﬂow cytometry of inguinal lymph nodes at 10 days postarthritis induction. Representative dot plots
indicating the percentage of IFN-γ (TH-1) and IL-17A (TH-17) producing T-helper cells are also shown. (B) Histological evaluation of joint pathology.
Values are presented for individual joints taken at day 10 post AIA (*p<0.05, **p<0.01). Representative parasagittal knee-joint sections stained
with haematoxylin, Safranin-O and Fast Green are shown for WT, FF and FFSt1 mice (scale bars, 500 mm). (C) Evaluation of synovial CD3 T-cell
inﬁltration by immunohistochemistry in WT, FF and FFSt1 synovial tissue (scale bars 200 mm). Quantiﬁcation of staining is also presented. Values
represent mean±SD (n=8/4/5 for WT/FF/FFSt1 mice, respectively).
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showed no signiﬁcant differences in arthritic index, inﬂamma-
tion, exudate, hyperplasia or erosion (ﬁgure 3A,B). Therefore,
IL-17A has minimal impact in local joint pathology during
inﬂammatory arthritis in gp130F/F mice.
DISCUSSION
While IL-17A and TH-17 cells are associated with the progres-
sion of autoimmune diseases, IL-17A targeted therapies have
delivered contrasting clinical outcomes. Inhibition of IL-17A in
psoriasis is extremely promising,4 5 but less favourable results
have come from trials in rheumatoid and psoriatic arthritis.19 20
Such varied clinical outcomes may reﬂect the nature of the under-
lining pathology and infer mechanistic differences in disease pro-
gression. To appreciate TH-17/IL-17A involvement in
inﬂammatory arthritis we used the gain-of-function gp130F/F
knock-in mouse model, which display enhanced IL-6/
gp130-mediated TH-17 commitment, increased IL-17A expres-
sion and severe AIA pathology.13 These responses are attributed
to enhanced and prolonged gp130-driven STAT1 and STAT3
activation. Importantly, deregulated gp130/STAT3 signalling is
associated with experimental models of autoimmunity and
cancer. Here, polymorphisms in several IL-6/STAT3 target genes
are considered risk factors for RA.21 Critically, STAT1 often
opposes the action of STAT3 (termed cross-regulation). Our
results reinforce this, with STAT1 negatively regulating the
STAT3 control of TH-17 cells in vitro. Prior AIA experiments
comparing gp130F/F with gp130F/F:Stat3+/− mice show that a
partial STAT3 deﬁciency ameliorates disease.13 We therefore pos-
tulated that gp130F/F:Stat1−/− mice would display severe joint
pathology. Although gp130F/F:Stat1−/− mice showed heightened
peripheral effector T-cell characteristics, joint inﬂammation in
gp130F/F:Stat1−/− mice closely resembles that seen in gp130F/F:
Stat3+/− mice. Thus, STAT1/STAT3 cross-regulation appears to
more prominently impact peripheral adaptive immunity.
Both STAT1 and STAT3 control chemokine-directed T-cell
trafﬁcking to inﬂamed tissue. STAT1 induces CXCR3 expression
Figure 3 Antigen-induced arthritis (AIA) pathology in gp130F/F mice is independent of IL-17A. (A) Evaluation of arthritic index (AI), inﬂammation,
exudate, hyperplasia and erosion scores in histological joint sections from gp130F/F (FF, closed circles) and gp130F/F:IL-17−/− (FFIL-17, open circles)
joint sections. Values are presented for individual joints taken at day 28 and day 35 post AIA. (C) Representative haematoxylin, Safranin-O and Fast
Green stained parasagittal joint sections taken on day-28 for FF and FFIL-17 mice (scale bars, 200 μM). Graphs represent mean±SD.
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on CD4 T-cells22 and local expression of CXCR3 ligands CXC-
chemokine ligand (CXCL)9, CXCL10 and CXCL11.23 24
Similarly, gp130/STAT3 activity controls inﬂammatory chemo-
kine expression and IL-6−/− mice show impaired T-cell inﬁltra-
tion and reduced T-cell CC-chemokine receptor (CCR)3, CCR5
and CXCR3 expression.25 Here, STAT1 and STAT3 did not
drive a selective trafﬁcking of deﬁned T-cell subsets, but instead
regulated all T-cell recruitment.25 We therefore generated
gp130F/F:Il17a−/− mice to investigate TH-17-driven joint path-
ology in gp130F/F mice. Critically, IL-17A did not majorly con-
tribute to the pathology seen in gp130F/F mice, and data were
consistent with results from inﬂammation-associated gastric
tumourigenesis in gp130F/F mice, where tumour progression
was also independent of IL-17A.16 While alternative effector
T-cell subsets may contribute to gp130-mediated joint pathology
in gp130F/F:Il17a−/− mice, it is also possible that other TH-17
effector cytokines (eg, IL-17F, GM-CSF) substitute for
IL-17A.1 26 27 Such ﬁndings may reﬂect recent trials in RA
where secukinumab (anti-IL-17A mAb) failed to meet its clinical
endpoint.19 20 The clinical efﬁcacy of a dual targeting strategy
for IL-17A/IL-17F (eg, brodalumab - the anti-IL-17 receptor A
mAb) remains to be determined. Loss of STAT1 or STAT3 activ-
ity had a profound effect on gp130-driven AIA, whereas loss of
IL-17A had minimal impact on disease. Therefore, gp130/STAT
signalling regulates T-cell responses through control of T-cell
effector functions and may determine the severity of local syn-
ovial inﬂammation by driving T-cell trafﬁcking.
In summary, our results illustrate that peripheral markers of
inﬂammatory disease may not correlate with local pathology
and can be an inadequate predictor of disease severity or local
joint pathology. When reﬂecting on clinical blockade of
IL-17A,4 5 19 20 our ﬁndings may be relevant in determining the
contrasting efﬁcacy of drugs like secukinumab in psoriasis and
RA.
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